Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1331Breast Neoplasms 687Carcinoma, Non-Small-Cell Lung 543Neoplasm Metastasis 436Lymphoma 435Leukemia, Myeloid, Acute 432Melanoma 402Prostatic Neoplasms 380Multiple Myeloma 366Lymphoma, Non-Hodgkin 356Ovarian Neoplasms 343Colorectal Neoplasms 333Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Pancreatic Neoplasms 328Leukemia, Lymphocytic, Chronic, B-Cell 323Leukemia 282Lung Neoplasms 275Glioblastoma 267Unspecified Adult Solid Tumor, Protocol Specific 257Recurrence 253Lymphoma, Follicular 248Lymphoma, Large B-Cell, Diffuse 245Brain Neoplasms 232Lymphoma, Mantle-Cell 210Hodgkin Disease 193Carcinoma, Renal Cell 193Head and Neck Neoplasms 192Myelodysplastic Syndromes 187Glioma 172Burkitt Lymphoma 172

Interventions

Moxifloxacin 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Completed × Long QT Syndrome × Clear all
NCT03258515 2020-02-20

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

AstraZeneca

Phase 1 Completed
45 enrolled

Long QT Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡